SEC Form 4 · accession 0000899866-17-000161

ALEXION PHARMACEUTICALS, INC. · ALXN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP. Global Operations

Period of report

Aug 31, 2017

Accepted (ET)

Sep 5, 2017 · 7:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000899866

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock, par value $.0001 per share^F1,F2	Aug 31, 2017	S	612	$142.00	D	26,092	D
Common Stock, par value $.0001 per share^F1	Sep 5, 2017	S	1,841	$145.81	D	24,251	D
Common Stock, par value $.0001 per share^F1	Sep 5, 2017	S	672	$147.00	D	23,579	D
Common Stock, par value $.0001 per share^F1,F3	Sep 5, 2017	S	600	$145.64	D	22,979	D
Common Stock, par value $.0001 per share^F4	Sep 5, 2017	S	650	$145.81	D	22,329	D

No Table II lines on this filing.

F1The transaction is made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
F2This transaction was executed in multiple trades through a broker-dealer at prices ranging from $142.00 - $142.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F3This transaction was executed in multiple trades through a broker-dealer at prices ranging from $145.51 - $146.51. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.
F4This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.